Stryker Co. (NYSE:SYK) Shares Acquired by Cozad Asset Management Inc.

Cozad Asset Management Inc. increased its position in Stryker Co. (NYSE:SYK) by 5.5% in the fourth quarter, Holdings Channel reports. The firm owned 888 shares of the medical technology company’s stock after purchasing an additional 46 shares during the quarter. Cozad Asset Management Inc.’s holdings in Stryker were worth $320,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of SYK. Signaturefd LLC lifted its holdings in Stryker by 2.0% in the fourth quarter. Signaturefd LLC now owns 9,285 shares of the medical technology company’s stock worth $3,343,000 after acquiring an additional 180 shares during the last quarter. Parallel Advisors LLC lifted its holdings in Stryker by 1.9% in the fourth quarter. Parallel Advisors LLC now owns 15,712 shares of the medical technology company’s stock worth $5,657,000 after acquiring an additional 300 shares during the last quarter. Cibc World Markets Corp lifted its holdings in Stryker by 78.9% in the fourth quarter. Cibc World Markets Corp now owns 83,234 shares of the medical technology company’s stock worth $29,968,000 after acquiring an additional 36,704 shares during the last quarter. SouthState Corp lifted its holdings in Stryker by 3.2% in the fourth quarter. SouthState Corp now owns 18,072 shares of the medical technology company’s stock worth $6,507,000 after acquiring an additional 563 shares during the last quarter. Finally, Creative Financial Designs Inc. ADV lifted its holdings in Stryker by 25.6% in the fourth quarter. Creative Financial Designs Inc. ADV now owns 398 shares of the medical technology company’s stock worth $143,000 after acquiring an additional 81 shares during the last quarter. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Stryker Price Performance

Shares of NYSE:SYK opened at $376.13 on Wednesday. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32. The stock has a market cap of $143.52 billion, a price-to-earnings ratio of 48.47, a PEG ratio of 2.93 and a beta of 0.95. Stryker Co. has a 12 month low of $314.93 and a 12 month high of $406.19. The stock’s 50 day moving average price is $383.71 and its 200 day moving average price is $373.82.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same period last year, the business earned $3.46 EPS. Equities research analysts anticipate that Stryker Co. will post 13.47 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be given a $0.84 dividend. The ex-dividend date is Monday, March 31st. This represents a $3.36 annualized dividend and a yield of 0.89%. Stryker’s dividend payout ratio (DPR) is 43.30%.

Insiders Place Their Bets

In other Stryker news, Director Ronda E. Stryker sold 201,392 shares of Stryker stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the transaction, the director now directly owns 3,642,075 shares in the company, valued at approximately $1,428,567,498. The trade was a 5.24 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Allan C. Golston sold 2,458 shares of Stryker stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total transaction of $941,586.06. Following the transaction, the director now owns 14,895 shares in the company, valued at approximately $5,705,827.65. The trade was a 14.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.90% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the stock. Morgan Stanley raised shares of Stryker from an “equal weight” rating to an “overweight” rating and raised their target price for the stock from $370.00 to $445.00 in a report on Monday, December 2nd. Citigroup reissued a “buy” rating and issued a $450.00 target price on shares of Stryker in a report on Wednesday, February 26th. Needham & Company LLC reaffirmed a “buy” rating and set a $442.00 price target on shares of Stryker in a report on Wednesday, January 29th. The Goldman Sachs Group set a $422.00 price target on Stryker in a report on Tuesday, March 4th. Finally, Argus set a $450.00 price target on Stryker in a report on Monday, February 3rd. Five equities research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $421.90.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.